Google
IMCR Stock Analysis — IMMUNOCORE HOLDINGS LTD (Healthcare >> Biotechnology)
IMCR FAQ
What is IMCR's P/E ratio?
IMMUNOCORE HOLDINGS LTD (IMCR) currently trades at a P/E ratio of 125.24.
What is IMCR's ROE?
IMMUNOCORE HOLDINGS LTD reports a Return on Equity (ROE) of -4.78%.
What is IMCR's dividend yield?
IMMUNOCORE HOLDINGS LTD offers a dividend yield of 0.00%.
What is IMCR's Quality Score?
Our AI rates IMCR's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IMCR?
Our AI Timing Score for IMCR is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IMCR belong to?
IMMUNOCORE HOLDINGS LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
IMCR AI Analysis Summary
Our AI summary for IMCR: IMMUNOCORE HOLDINGS LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 125.24, ROE of -4.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 33.81
Price
-0.06
(-0.18%)
Day Change
|
|
|---|
IMCR, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 33.81 |
| PBV / Sector |
4.38 / 5.20
|
| Earning Per Share | -0.37 |
| PE / Sector |
125.24 / 19.97
|
| PEG or PE/Growth / Sector |
-7.46 / 1.22
|
| Average 1M Daily Value |
19.00 M
GREAT
|
| Average 1W Daily Value |
11.49 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:00 |
| Symbol | IMCR |
| Name | IMMUNOCORE HOLDINGS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 50.87 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,722.82 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
Phone: 44 12 3543 8600
Website: https://www.immunocore.com
Employees: 524
Sector: Healthcare >> Biotechnology
Description: Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap